Fareston
Antiestrogen for Hormone Receptor-Positive Breast Cancer
Quick Facts About Fareston
Key Takeaways About Fareston
- Hormone receptor-positive breast cancer treatment: Fareston is used specifically for postmenopausal women with estrogen receptor-positive (ER+) breast cancer, blocking the hormone signals that drive tumour growth
- QT prolongation risk: Fareston can affect the heart’s electrical activity (QT interval prolongation), making ECG monitoring important, especially if you have pre-existing cardiac conditions or take other QT-prolonging drugs
- Once-daily dosing: Taken as a single 60 mg tablet each day, with or without food, making it convenient for long-term therapy
- Regular gynaecological monitoring required: Endometrial changes including hyperplasia, polyps, and in very rare cases endometrial cancer may occur, so regular gynaecological examinations are recommended during treatment
- Significant drug interactions: Many common medications, particularly QT-prolonging drugs, CYP3A4 inhibitors, and anticoagulants, can interact with Fareston and require dose adjustments or avoidance
What Is Fareston and What Is It Used For?
Fareston (toremifene) is an antiestrogen medication belonging to the selective estrogen receptor modulator (SERM) class. It is used to treat hormone receptor-positive breast cancer in postmenopausal women by blocking the growth-promoting effects of estrogen on breast cancer cells.
Fareston contains the active substance toremifene, which competitively binds to estrogen receptors in breast tissue. Estrogen, a naturally occurring female sex hormone, can stimulate the growth of certain breast cancers that express estrogen receptors on their cell surfaces. By occupying these receptors, toremifene prevents estrogen from exerting its proliferative effect, effectively slowing or stopping the growth of hormone-dependent tumour cells.
Breast cancer is the most common cancer in women worldwide, and approximately 70–80% of all breast cancers are classified as hormone receptor-positive (HR+), meaning they have receptors for estrogen, progesterone, or both. Endocrine therapy, which includes SERMs like toremifene and tamoxifen, aromatase inhibitors, and selective estrogen receptor degraders (SERDs), forms a cornerstone of treatment for these hormone-sensitive cancers. The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) both include SERMs as an accepted treatment option for hormone receptor-positive breast cancer.
Toremifene was first approved by regulatory authorities in the 1990s and is structurally related to tamoxifen, with the addition of a chlorine atom on its side chain. Clinical trials, including large randomised studies, have demonstrated that toremifene has comparable efficacy to tamoxifen in terms of response rate, time to disease progression, and overall survival in postmenopausal women with advanced hormone receptor-positive breast cancer. It is primarily indicated for metastatic disease in postmenopausal women, although its use may extend to other clinical settings based on physician assessment.
It is important to understand that Fareston is a long-term treatment that works by modifying the hormonal environment of the tumour. It does not provide immediate symptom relief but rather aims to control disease progression over weeks and months of consistent use. Treatment duration is determined by your oncologist based on your individual clinical situation, tumour response, and tolerability.
Toremifene is classified as a nonsteroidal antiestrogen. Unlike aromatase inhibitors, which reduce estrogen production, SERMs like toremifene work by blocking estrogen from binding to its receptors. This means toremifene has both antiestrogen effects in breast tissue and partial estrogen-like (agonist) effects in other tissues, such as bone and the cardiovascular system. This mixed profile distinguishes SERMs from pure antiestrogens and aromatase inhibitors.
What Should You Know Before Taking Fareston?
Before starting Fareston, inform your doctor about all medical conditions, particularly heart problems, liver disease, a history of blood clots, or endometrial disorders. Fareston is contraindicated in patients with endometrial hyperplasia, severe liver impairment, QT prolongation, uncorrected electrolyte imbalances, and certain cardiac conditions.
Contraindications
You should not take Fareston if any of the following apply to you:
- Allergy to toremifene or any of the other ingredients in Fareston (listed in the composition section below)
- Endometrial hyperplasia (abnormal thickening of the uterine lining) – toremifene can further stimulate endometrial growth due to its partial estrogen agonist activity
- Severe liver impairment – toremifene is extensively metabolised by the liver, and impaired hepatic function can lead to dangerously elevated drug levels
- Congenital or acquired QT prolongation – Fareston can prolong the QT interval on an ECG, which may result in life-threatening cardiac arrhythmias such as torsades de pointes
- Uncorrected hypokalaemia (low potassium levels) – electrolyte imbalances increase the risk of QT prolongation and cardiac arrhythmias
- Clinically significant bradycardia (very slow heart rate)
- Heart failure
- History of cardiac arrhythmias
- Concurrent use of QT-prolonging medications (see the drug interactions section)
Warnings and Precautions
Talk to your doctor or pharmacist before taking Fareston if you have or have had any of the following conditions:
- Uncontrolled diabetes mellitus – your blood sugar levels may need more frequent monitoring during treatment
- Severely impaired general condition – your doctor will assess whether Fareston is appropriate for your clinical situation
- History of blood clots such as deep vein thrombosis (DVT) or pulmonary embolism – toremifene, like other SERMs, is associated with an increased risk of thromboembolic events
- Abnormal heart rhythm during treatment – if you develop palpitations, dizziness, or fainting while taking Fareston, contact your doctor immediately, as these may indicate QT prolongation or arrhythmia. Your doctor may recommend stopping treatment and performing an ECG
- Any heart condition, including chest pain (angina pectoris) – cardiac monitoring may be necessary
- Bone metastases – elevated blood calcium levels (hypercalcaemia) may occur at the beginning of treatment. Your doctor will monitor your calcium levels regularly, particularly during the first weeks of therapy
- Lactose intolerance – Fareston tablets contain 28.5 mg of lactose (as monohydrate) per tablet. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine
You should undergo a gynaecological examination before starting treatment with Fareston and at least once per year during therapy. Your doctor will regularly check for high blood pressure, diabetes, history of hormone replacement therapy, and whether you are overweight (BMI above 30), as these factors may influence treatment management.
Pregnancy and Breastfeeding
Fareston must not be used during pregnancy or breastfeeding. Toremifene is an antiestrogen agent that could potentially harm the developing foetus. Since Fareston is indicated for the treatment of breast cancer in postmenopausal women, pregnancy is generally not expected. However, if you are of childbearing potential, you should use effective non-hormonal contraception during treatment and for several months after discontinuation. Inform your doctor immediately if you suspect you may be pregnant while taking Fareston.
It is not known whether toremifene passes into breast milk. Given the potential risks to the nursing infant and the seriousness of the condition being treated, breastfeeding should be discontinued before starting Fareston therapy.
Driving and Operating Machinery
Fareston has no known effect on the ability to drive or operate machinery. However, some patients may experience dizziness, fatigue, or visual disturbances during treatment. If you experience any of these symptoms, exercise caution when driving or using machines until the symptoms resolve.
How Does Fareston Interact with Other Drugs?
Fareston has significant interactions with many medications, particularly drugs that prolong the QT interval, CYP3A4 inhibitors and inducers, anticoagulants, and thiazide diuretics. Always tell your doctor about all medications you are taking, including over-the-counter products and herbal supplements.
Toremifene is primarily metabolised in the liver by the cytochrome P450 enzyme CYP3A4. Drugs that inhibit CYP3A4 can increase toremifene blood levels (potentially increasing toxicity and QT prolongation risk), while drugs that induce CYP3A4 can decrease toremifene levels (potentially reducing therapeutic efficacy). Additionally, because Fareston can prolong the QT interval, concurrent use with other QT-prolonging drugs is strictly contraindicated due to the additive risk of serious cardiac arrhythmias.
Contraindicated Combinations (Must Not Be Used Together)
| Drug | Category | Risk |
|---|---|---|
| Quinidine, Hydroquinidine, Disopyramide, Amiodarone, Sotalol, Dofetilide, Ibutilide | Antiarrhythmic agents | Additive QT prolongation – risk of torsades de pointes and fatal cardiac arrhythmias |
| Phenothiazines, Pimozide, Sertindole, Haloperidol, Sultoride | Antipsychotics (neuroleptics) | Additive QT prolongation – increased risk of ventricular arrhythmias |
| Moxifloxacin, Erythromycin (IV), Pentamidine, Halofantrine | Anti-infectives | QT prolongation – serious cardiac rhythm disturbances |
| Terfenadine, Astemizole, Mizolastine | Antihistamines | QT prolongation – cardiac arrhythmia risk |
| Cisapride, Vincamine (IV), Bepridil, Diphemanil | Miscellaneous | QT prolongation – potentially fatal arrhythmias |
Major Interactions (Use with Caution)
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Warfarin | Anticoagulant | Toremifene may enhance the anticoagulant effect of warfarin, increasing bleeding risk | Monitor INR closely; warfarin dose adjustment may be needed |
| Thiazide diuretics | Diuretic | May cause hypokalaemia, increasing the risk of QT prolongation with toremifene | Monitor potassium levels regularly; correct any electrolyte imbalances |
| Ketoconazole, Itraconazole, Voriconazole, Posaconazole | Antifungals (CYP3A4 inhibitors) | Significantly increase toremifene blood levels, raising QT prolongation and toxicity risk | Avoid combination if possible; if used, monitor ECG and toremifene levels |
| Erythromycin (oral), Clarithromycin, Telithromycin | Macrolide antibiotics (CYP3A4 inhibitors) | Increase toremifene levels; some also independently prolong QT | Use alternative antibiotics when possible; monitor cardiac function |
| Ritonavir, Nelfinavir | HIV protease inhibitors (CYP3A4 inhibitors) | Strong CYP3A4 inhibition increases toremifene exposure | Use with caution; monitor for adverse effects and QT prolongation |
| Carbamazepine, Phenytoin, Phenobarbital | Antiepileptics (CYP3A4 inducers) | Decrease toremifene blood levels, potentially reducing therapeutic effectiveness | Consider alternative antiepileptic agents; monitor treatment response |
If you are admitted to hospital or prescribed any new medication, always inform your healthcare provider that you are taking Fareston. This is particularly important because of the significant cardiac risks associated with QT-prolonging drug combinations. Your oncologist or cardiologist may recommend periodic ECG monitoring during treatment, especially if you have additional risk factors for arrhythmia.
What Is the Correct Dosage of Fareston?
The standard dose of Fareston is one 60 mg tablet taken once daily by mouth. The tablet should be swallowed whole and can be taken with or without food. Always take Fareston exactly as prescribed by your doctor.
Fareston is available as a single-strength formulation containing 60 mg of toremifene (as citrate). The dosing regimen is straightforward: one tablet once daily, taken at the same time each day for consistency. Unlike many other medications, there is no dose titration or adjustment for most patient populations. Your oncologist will determine the duration of treatment based on your disease status, treatment response, and tolerability.
Adults (Postmenopausal Women)
Hormone Receptor-Positive Breast Cancer
Standard dose: 60 mg (one tablet) once daily
Administration: Swallow the tablet whole with water. Can be taken with or without food.
Treatment is typically continued as long as clinical benefit is observed and the medication is tolerated. Your oncologist will review your treatment at regular intervals. The antiestrogen effect of toremifene develops gradually over weeks of consistent use; do not expect immediate changes in your condition.
Special Populations
No specific dose adjustments are recommended for elderly patients or patients with mild to moderate renal impairment, as toremifene is primarily metabolised by the liver and only a small fraction is excreted renally. However, patients with severe hepatic impairment should not take Fareston, as impaired liver function significantly alters the drug’s metabolism and increases the risk of toxicity.
Fareston is not indicated for use in children. There is no relevant indication for toremifene in the paediatric population, and safety and efficacy data are not available for patients under 18 years of age.
Missed Dose
If you forget to take a dose of Fareston, take the next tablet at the usual time and continue your treatment as directed. Do not take a double dose to make up for a missed one. If you have missed several consecutive doses, contact your doctor for advice on how to resume your treatment schedule. Consistent daily dosing is important for maintaining therapeutic drug levels and optimising treatment efficacy.
Overdose
If you take more Fareston tablets than prescribed, contact your doctor, pharmacist, or nearest hospital emergency department immediately. Symptoms of overdose may include dizziness and headache. Due to the QT-prolonging properties of toremifene, an overdose may increase the risk of serious cardiac arrhythmias. There is no specific antidote for toremifene overdose; treatment is supportive and symptomatic, with cardiac monitoring recommended.
Stopping Fareston
Do not stop taking Fareston unless your doctor has specifically recommended it. Discontinuing endocrine therapy for breast cancer without medical supervision may affect treatment outcomes and disease control. If you experience intolerable side effects, discuss alternative treatment options with your oncologist before stopping the medication. Your doctor may switch you to a different endocrine therapy, such as an aromatase inhibitor or another SERM, depending on your clinical circumstances.
What Are the Side Effects of Fareston?
The most common side effects of Fareston are hot flushes and sweating, which affect more than 1 in 10 people. Other common side effects include fatigue, dizziness, depression, nausea, vomiting, rash, itching, oedema, uterine bleeding, and vaginal discharge. Fareston can also cause QT prolongation visible on ECG.
Like all medicines, Fareston can cause side effects, although not everyone experiences them. Many side effects are related to the antiestrogen mechanism of action and are similar to those seen with tamoxifen and other SERMs. The severity and frequency of side effects may vary between individuals. If any side effect becomes severe, persistent, or concerning, contact your doctor promptly.
- Swelling or tenderness in the calf (possible deep vein thrombosis)
- Unexplained shortness of breath or sudden chest pain (possible pulmonary embolism)
- Abnormal vaginal bleeding or changes in vaginal discharge
- Palpitations, dizziness, or fainting (possible cardiac arrhythmia due to QT prolongation)
- Yellowing of the skin or eyes (jaundice – possible liver damage)
Very Common
May affect more than 1 in 10 people
- Hot flushes (vasomotor symptoms)
- Excessive sweating (hyperhidrosis)
Common
May affect up to 1 in 10 people
- Fatigue and tiredness
- Dizziness
- Depression
- Nausea and vomiting
- Skin rash
- Itching (pruritus)
- Oedema (swelling due to fluid retention)
- Uterine bleeding
- Vaginal discharge (leucorrhoea)
Uncommon
May affect up to 1 in 100 people
- Headache
- Sleep disturbances (insomnia)
- Weight gain
- Constipation
- Loss of appetite (anorexia)
- Endometrial thickening (endometrial hyperplasia)
- Thromboembolic events (blood clots in lungs or legs)
- Shortness of breath (dyspnoea)
Rare and Very Rare
May affect up to 1 in 1,000 people or fewer
- Vertigo
- Endometrial polyps
- Elevated liver enzymes (transaminases)
- Hair loss (alopecia) – very rare
- Transient corneal opacity (reversible eye changes) – very rare
- Endometrial cancer – very rare
- Jaundice (yellowing of skin and eyes) – very rare
- Leucopenia (low white blood cell count) – frequency unknown
- Anaemia (low red blood cell count) – frequency unknown
- Thrombocytopenia (low platelet count) – frequency unknown
- Hepatitis (liver inflammation) – frequency unknown
Fareston can cause abnormal changes in the electrical activity of the heart (QT prolongation), which is detectable on an electrocardiogram (ECG). This is generally asymptomatic but can, in rare cases, lead to serious or life-threatening cardiac arrhythmias. Your doctor may recommend ECG monitoring, particularly at the start of treatment and if you have additional risk factors.
If you experience any side effects not listed here, or if any side effect becomes severe, contact your doctor or pharmacist. Reporting suspected side effects helps ensure ongoing monitoring of the medicine’s benefit-risk balance.
How Should You Store Fareston?
Store Fareston tablets at room temperature, out of the reach and sight of children. No special storage conditions are required. Do not use after the expiry date printed on the packaging.
Fareston does not require any special storage conditions. Keep the tablets in the original packaging to protect from light and moisture. Store the medicine at room temperature and ensure it remains inaccessible to children and pets.
Check the expiry date on the label before taking any tablets. The expiry date refers to the last day of the stated month. Do not use Fareston after this date, as the chemical stability and therapeutic effectiveness of the medication cannot be guaranteed beyond the expiry date.
Do not dispose of unused or expired tablets by flushing them down the toilet or throwing them in household waste. Return any unwanted medication to your pharmacy for proper disposal. This helps protect the environment from pharmaceutical contamination and prevents accidental ingestion by others.
What Does Fareston Contain?
Each Fareston tablet contains 60 mg of toremifene (as toremifene citrate) as the active ingredient, along with several inactive ingredients including maize starch, lactose monohydrate, povidone, sodium starch glycolate, microcrystalline cellulose, colloidal anhydrous silica, and magnesium stearate.
Active Ingredient
The active substance is toremifene. Each tablet contains 60 mg of toremifene, present as toremifene citrate. Toremifene citrate is a white to off-white crystalline powder that is practically insoluble in water but soluble in organic solvents. The citrate salt form ensures optimal stability and bioavailability of the active compound.
Inactive Ingredients (Excipients)
The other ingredients in Fareston tablets are:
- Maize starch – used as a filler and disintegrant to help the tablet break apart after swallowing
- Lactose monohydrate (28.5 mg per tablet) – a sugar-based filler. Patients with lactose intolerance should consult their doctor before taking Fareston
- Povidone – a binder that helps hold the tablet together
- Sodium starch glycolate – a disintegrant that helps the tablet dissolve in the gastrointestinal tract
- Microcrystalline cellulose – a filler and binder
- Colloidal anhydrous silica – a flow agent that improves tablet manufacturing consistency
- Magnesium stearate – a lubricant that prevents the tablet from sticking to manufacturing equipment
Sodium Content
This medicine contains less than 1 mmol (23 mg) sodium per tablet, meaning it is essentially “sodium-free”. This is relevant for patients on a sodium-restricted diet.
Tablet Appearance and Packaging
Fareston 60 mg tablets: White, round, flat tablets with bevelled edges, debossed with “TO 60” on one side.
Available in packs of 30 and 100 tablets. Not all pack sizes may be marketed in every country.
Manufacturer
Fareston is manufactured by Orion Corporation Orion Pharma, Finland. The marketing authorisation is held by Orion Corporation, Espoo, Finland.
How Does Fareston Work in the Body?
Fareston works by competitively binding to estrogen receptors on breast cancer cells, blocking estrogen from stimulating tumour growth. As a selective estrogen receptor modulator (SERM), toremifene has antiestrogen effects in breast tissue while exerting partial estrogen agonist effects in other tissues such as bone.
Estrogen plays a critical role in the growth and proliferation of hormone receptor-positive breast cancers. In these tumours, estrogen binds to intracellular estrogen receptors (ER), forming a hormone-receptor complex that translocates to the cell nucleus. There, it activates the transcription of genes involved in cell proliferation, leading to increased tumour cell division and growth.
Toremifene competes with estrogen for binding to the estrogen receptor, forming a toremifene-receptor complex that does not effectively activate the transcription of estrogen-responsive genes in breast tissue. By occupying the receptor without triggering the proliferative signalling cascade, toremifene effectively blocks the growth-promoting effect of estrogen on breast cancer cells. This leads to inhibition of DNA synthesis, reduced cell division, and ultimately slowed or arrested tumour growth.
As a selective estrogen receptor modulator, toremifene exhibits tissue-selective activity. While it acts as an antiestrogen in breast tissue (blocking estrogen-driven tumour growth), it has partial estrogen-like (agonist) effects in other tissues. For example, toremifene may have a beneficial effect on bone mineral density by mimicking some of estrogen’s bone-protective actions, and it can have favourable effects on serum lipid profiles. However, this partial agonist activity also accounts for some side effects, particularly the stimulatory effect on the endometrium, which necessitates regular gynaecological monitoring.
Pharmacokinetic Profile
After oral administration, toremifene is well absorbed from the gastrointestinal tract. Peak plasma concentrations are typically reached within 3 hours of dosing. Food does not significantly affect the absorption of toremifene, allowing the tablet to be taken with or without meals.
Toremifene is extensively bound to plasma proteins (more than 99.5%), primarily to albumin. It is metabolised in the liver, predominantly by the CYP3A4 enzyme system. The principal metabolite, N-demethyltoremifene, retains antiestrogen activity and contributes to the overall therapeutic effect. Several other metabolites are formed, most of which are inactive.
The elimination half-life of toremifene is approximately 5 days (around 120 hours), which is considerably longer than that of many other cancer medications. This long half-life supports once-daily dosing and ensures sustained therapeutic drug levels. Toremifene and its metabolites are eliminated primarily through the faeces, with only a small proportion excreted in the urine. Steady-state plasma concentrations are typically achieved within 4–6 weeks of daily dosing.
The long half-life of toremifene means that a single missed dose is unlikely to significantly affect therapeutic drug levels. However, consistent daily dosing is still recommended to maintain optimal and stable blood concentrations throughout treatment. If you need to discontinue treatment, be aware that the drug and its active metabolites may remain in your body for several weeks after the last dose.
Frequently Asked Questions About Fareston
Fareston (toremifene) is used for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It belongs to the selective estrogen receptor modulator (SERM) class and works by blocking the effects of estrogen on breast cancer cells, thereby inhibiting tumour growth. It is taken as a 60 mg tablet once daily.
The most common side effects of Fareston are hot flushes and sweating, which affect more than 1 in 10 people. Other common side effects include fatigue, dizziness, depression, nausea, vomiting, skin rash, itching, oedema (swelling), uterine bleeding, and vaginal discharge. Most side effects are manageable and should be discussed with your doctor if they become persistent or severe.
Yes, Fareston can prolong the QT interval on an electrocardiogram (ECG), which is a measure of the heart’s electrical activity. In rare cases, this can lead to serious heart rhythm disturbances (arrhythmias), including torsades de pointes. You should not take Fareston if you have a history of QT prolongation, heart failure, bradycardia, or cardiac arrhythmias, or if you are taking other medications that prolong the QT interval. Your doctor may recommend ECG monitoring during treatment.
Both Fareston (toremifene) and tamoxifen are selective estrogen receptor modulators (SERMs) used for hormone receptor-positive breast cancer. They have similar mechanisms of action and comparable efficacy in clinical trials. However, they differ in their chemical structure (toremifene has an additional chlorine atom), metabolic pathways, and some side effect profiles. Toremifene has a longer half-life (approximately 5 days vs. 5–7 days for tamoxifen), and some studies suggest differences in genotoxic potential. Your oncologist will choose the most appropriate treatment based on your individual circumstances.
No, Fareston must not be used during pregnancy or breastfeeding. Toremifene is an antiestrogen agent that could potentially harm the developing foetus. Since Fareston is indicated for postmenopausal breast cancer, pregnancy is generally not expected. However, if you are of childbearing potential, effective non-hormonal contraception should be used during treatment. Inform your doctor immediately if you suspect pregnancy.
The duration of Fareston treatment is determined by your oncologist based on your individual clinical circumstances, including the type and stage of breast cancer, treatment response, and any side effects. Endocrine therapy for breast cancer is typically a long-term treatment that may continue for months or years. Never stop taking Fareston without consulting your doctor, as this could affect your treatment outcomes and disease control.
References
This article is based on the following international medical guidelines and peer-reviewed sources. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
- Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019;30(8):1194–1220. doi:10.1093/annonc/mdz173
- Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology. 2019;37(5):423–438.
- International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans – Tamoxifen and Toremifene. Volume 100A. Lyon: IARC; 2012.
- European Medicines Agency (EMA). Fareston (toremifene) – Summary of Product Characteristics. EMA product information database. Accessed January 2026.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- Vogel CL, Johnston MA, Capers C, Braccia D. Toremifene for breast cancer: a review of 20 years of data. Clinical Breast Cancer. 2014;14(1):1–9. doi:10.1016/j.clbc.2013.10.014
- Lewis JD, Chagpar AB, Shaughnessy EA, et al. Toremifene vs tamoxifen in advanced breast cancer: a meta-analysis of randomized trials. Breast Cancer Research and Treatment. 2010;121(2):293–302.
- National Institute for Health and Care Excellence (NICE). Early and locally advanced breast cancer: diagnosis and management. NICE guideline [NG101]. Updated 2023.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in oncology, clinical pharmacology, and internal medicine.
Medical Writers
Board-certified physicians specialising in oncology and clinical pharmacology with documented academic and clinical experience in breast cancer treatment.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (ESMO, ASCO, NICE, WHO), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.